Show simple item record

dc.contributor.authorOlloquequi J.
dc.contributor.authorCornejo-Córdova E.
dc.contributor.authorVerdaguer E.
dc.contributor.authorSoriano F.X.
dc.contributor.authorBinvignat O.
dc.contributor.authorAuladell C.
dc.contributor.authorCamins A.
dc.date.accessioned2020-09-02T22:24:48Z
dc.date.available2020-09-02T22:24:48Z
dc.date.issued2018
dc.identifier10.1177/0269881118754680
dc.identifier.citation32, 3, 265-275
dc.identifier.issn02698811
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5651
dc.descriptionNeurological and psychiatric disorders are leading contributors to the global disease burden, having a serious impact on the quality of life of both patients and their relatives. Although the molecular events underlying these heterogeneous diseases remain poorly understood, some studies have raised the idea of common mechanisms involved. In excitotoxicity, there is an excessive activation of glutamate receptors by excitatory amino acids, leading to neuronal damage. Thus, the excessive release of glutamate can lead to a dysregulation of Ca2+ homeostasis, triggering the production of free radicals and oxidative stress, mitochondrial dysfunction and eventually cell death. Although there is a consensus in considering excitotoxicity as a hallmark in most neurodegenerative diseases, increasing evidence points to the relevant role of this pathological mechanism in other illnesses affecting the central nervous system. Consequently, antagonists of glutamate receptors are used in current treatments or in clinical trials in both neurological and psychiatric disorders. However, drugs modulating other aspects of the excitotoxic mechanism could be more beneficial. This review discusses how excitotoxicity is involved in the pathogenesis of different neurological and psychiatric disorders and the promising strategies targeting the excitotoxic insult. © 2018, © The Author(s) 2018.
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.subjectAlzheimer’s disease
dc.subjectautism spectrum disorder
dc.subjectdepression
dc.subjectGlutamate
dc.subjectstroke
dc.subjectacetylcysteine
dc.subjectcalcium ion
dc.subjectcycloserine
dc.subjectfludrocortisone
dc.subjectfree radical
dc.subjectglutamate receptor
dc.subjectglutamic acid
dc.subjectketamine
dc.subjectmemantine
dc.subjectn methyl dextro aspartic acid receptor blocking agent
dc.subjectneu 2000kwl
dc.subjectriluzole
dc.subjecttissue plasminogen activator
dc.subjectunclassified drug
dc.subjectursodeoxycholic acid
dc.subjectglutamate receptor
dc.subjectglutamic acid
dc.subjectAlzheimer disease
dc.subjectamyotrophic lateral sclerosis
dc.subjectautism
dc.subjectbrain ischemia
dc.subjectcell death
dc.subjectdepression
dc.subjectdisorders of mitochondrial functions
dc.subjectdrug targeting
dc.subjectexcitotoxicity
dc.subjecthuman
dc.subjectmental disease
dc.subjectneurologic disease
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectParkinson disease
dc.subjectpathogenesis
dc.subjectpriority journal
dc.subjectReview
dc.subjectschizophrenia
dc.subjectsignal transduction
dc.subjectanimal
dc.subjectmental disease
dc.subjectmetabolism
dc.subjectnerve cell
dc.subjectneurologic disease
dc.subjectpathology
dc.subjectAnimals
dc.subjectGlutamic Acid
dc.subjectHumans
dc.subjectMental Disorders
dc.subjectNervous System Diseases
dc.subjectNeurons
dc.subjectReceptors, Glutamate
dc.titleExcitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record